Tyrosine kinase inhibitors disrupt the process that manages how your cells mature and divide. That approach requires: The breathtaking results demonstrated with imatinib mesylate (aka Gleevec) focusing on crack level cluster (Bcr)-Abelson (Abl) fusion protein in Serious myeloid leukemia (CML) bri